The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now

247wallst.com - 2026-07-12 22:44:47

Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.

fool.com - 2026-07-09 03:55:00

REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.

globenewswire.com - 2026-07-07 09:23:00

The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental ​treatment for patients with metastatic pancreatic cancer.

reuters.com - 2026-07-07 09:09:39

Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.

fool.com - 2026-07-06 18:10:00

Revolution Medicines has taken a new approach to the treatment of certain cancers. The company's lead product is approaching the regulatory review stage.

fool.com - 2026-07-05 19:15:00

REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC).

globenewswire.com - 2026-07-02 08:00:00

Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year.

fool.com - 2026-07-01 16:37:00

REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany.

globenewswire.com - 2026-06-24 19:31:00

Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.

zacks.com - 2026-06-24 11:16:07

Biotech M&A is back in the spotlight. Big Pharma faces patent cliffs over the next several years, and recent dealmaking, including the AbbVie (NYSE: ABBV | ABBV Price Prediction) acquisition of Apogee Therapeutics, signals buyers are willing to pay up for de-risked clinical assets in oncology, obesity, and cell therapy.

247wallst.com - 2026-06-24 07:55:10

Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D.

globenewswire.com - 2026-06-22 08:00:00

Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.

seekingalpha.com - 2026-06-13 05:04:54

Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs.

fool.com - 2026-06-11 06:45:00

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:35:45

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

fool.com - 2026-06-05 08:45:31

Can the drugmaker justify its valuation?

fool.com - 2026-06-05 02:45:00

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

seekingalpha.com - 2026-06-01 12:14:05

Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.

zacks.com - 2026-06-01 10:16:24

Revolution Medicines (RVMD) moved higher in US premarket trading after fresh data added more weight to the story around daraxonrasib, its experimental pancreati

gurufocus.com - 2026-06-01 09:26:00

Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

feeds.benzinga.com - 2026-05-31 22:43:12

REDWOOD CITY, Calif. , May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

globenewswire.com - 2026-05-31 08:06:00

Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine

globenewswire.com - 2026-05-31 08:06:00

Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.

fool.com - 2026-05-28 08:07:09

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

globenewswire.com - 2026-05-21 16:05:00

GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

benzinga.com - 2026-05-19 09:50:31

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

benzinga.com - 2026-05-15 11:47:23

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from ​Revolution Medicines while they await what they hope will be a speedy FDA approval.

reuters.com - 2026-05-14 06:04:56

Expense ratios, diversification, and sector tilts set these two small-cap ETFs apart. Explore how their strategies impact risk and long-term performance.

fool.com - 2026-05-11 11:13:02

Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.

zacks.com - 2026-05-07 13:50:13

Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer

globenewswire.com - 2026-05-06 18:00:00

An experimental drug from Revolution Medicines that nearly ​doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate ‌of mostly low-grade side effects, researchers reported on Wednesday.

reuters.com - 2026-05-06 17:01:54

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration AACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition Strengthened financial position with financings totaling $2.2 billion in gross proceeds Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

globenewswire.com - 2026-05-06 16:02:00

The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution ​Medicines' pill for patients with previously treated ‌pancreatic cancer, the company said on Friday.

reuters.com - 2026-05-01 12:54:46

Compare how sector allocations, cost, and diversification set these two leading small-cap ETFs apart for investors seeking broad market exposure.

fool.com - 2026-05-01 09:06:01

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close.

globenewswire.com - 2026-04-29 16:05:00

Expense ratios, diversification, and recent returns reveal key differences between these two leading small-cap ETFs.

fool.com - 2026-04-29 13:08:37

Compare how expense ratios, yield, and portfolio breadth set these two small-cap ETFs apart in risk and income profile.

fool.com - 2026-04-29 11:27:59

Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.

wsj.com - 2026-04-28 05:30:00

Investors have grown excited about Revolution Medicines due to its promising pancreatic cancer drug, daraxonrasib. Daraxonrasib significantly extended the life of patients in a recent clinical trial.

fool.com - 2026-04-27 11:00:00

Explore how these two small-cap ETFs differ in diversification, risk, and portfolio strategy to help refine your investment approach.

fool.com - 2026-04-24 10:50:27

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two Phase 1/2 trials of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Data from the daraxonrasib combination cohort will be presented in a late-breaking mini-symposium, and data from the monotherapy cohort will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 21, 2026.

globenewswire.com - 2026-04-21 17:35:00

Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.

wsj.com - 2026-04-21 17:35:00

Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer

globenewswire.com - 2026-04-21 17:30:00

REDWOOD CITY, Calif. , April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026 in Chicago.

globenewswire.com - 2026-04-21 11:23:01

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago.

globenewswire.com - 2026-04-21 11:23:00

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT.

globenewswire.com - 2026-04-19 14:00:00

REDWOOD CITY, Calif. , April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC).

globenewswire.com - 2026-04-19 14:00:00

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Mark Goldsmith sold 120,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the transaction, the insider owned 276,698 shares in the

defenseworld.net - 2026-04-19 04:05:03

REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its concurrent upsized public offerings of 12,147,887 shares of its common stock at a public offering price of $142.00 per share and $500.0 million aggregate principal amount of 0.50% convertible senior notes due 2033 (the “notes”). The shares of common stock issued and sold in the common stock offering include 1,584,506 shares issued upon exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offerings, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, were approximately $2,225.0 million.

globenewswire.com - 2026-04-17 16:02:00